EMA gives thumbs-down to GSK's mul­ti­ple myelo­ma drug, PTC's Duchenne can­di­date

Mul­ti­ple myelo­ma drug Blenrep and Duchenne mus­cu­lar dy­s­tro­phy ther­a­peu­tic Translar­na did not make the Eu­ro­pean Med­i­cines Agency’s cut for full mar­ket­ing au­tho­riza­tion, the agency an­nounced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER